(E)-methyl 5-(methyl 3-propenoate)-2-furanoate | 58293-86-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: (E)-methyl 5-(methyl 3-propenoate)-2-furanoate
• 英文别名: (E)-methyl 5-(methyl-3-propenoate)-2-furanoate；methyl β-(5-methoxycarbonyl-2-furyl)acrylate；(E)-Methyl 5-(3-methoxy-3-oxoprop-1-en-1-yl)furan-2-carboxylate；methyl 5-[(E)-3-methoxy-3-oxoprop-1-enyl]furan-2-carboxylate
• CAS: 58293-86-0
• 化学式: C₁₀H₁₀O₅
• 分子量: 210.186
• InChiKey: YHEHEVFHOZQFHC-GQCTYLIASA-N

物化性质

• 熔点：
  73-74 °C(Solv: chloroform (67-66-3))
• 沸点：
  329.4±32.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  65.7
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2932190090

反应信息

• 作为产物：
  描述：

  5-溴-2-糠酸甲酯 、 丙烯酸甲酯（MA） 在 palladium diacetate 、 三乙胺 、 三甲氧基磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以85%的产率得到(E)-methyl 5-(methyl 3-propenoate)-2-furanoate
  参考文献：
  名称：

  使用Heck方法学制备3-（杂芳基）丙烯酸甲酯的制备路线

  摘要：

  使用杂芳烃卤化物与由Pd（OAc）2 / P（OCH 3）3介导的丙烯酸甲酯进行Heck偶联制备3-（杂芳基）丙烯酸甲酯。反应非常高效（反应时间在60到120分钟之间），可扩展至100克杂芳烃卤化物。分离的产率为76％至99％。

  DOI：

  10.1021/op050106k

文献信息

• [EN] CHROMANE, ISOCHROMANE AND DIHYDROISOBENZOFURAN DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE<br/>[FR] DÉRIVÉS DE CHROMANE, D'ISOCHROMANE ET DE DIHYDROISOBENZOFURANE EN TANT QUE MODULATEURS ALLOSTÉRIQUES NÉGATIFS DE MGLUR2, COMPOSITIONS ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2018063955A1

  公开（公告）日：2018-04-05

  The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from (II), (III), (IV), and (V), and ring B, n, R1, R2, R2A, R3, and R3A are as defined herein. The compounds of the invention are useful as mGluR2 inhibitors, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a patient for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, mild congnitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

  本发明提供了某些取代的色苷、异色苷和二氢异苯并呋喃化合物的化学结构（I），或其药学上可接受的盐，其中环A是从（II）、（III）、（IV）和（V）中选择的基团，环B、n、R1、R2、R2A、R3和R3A如本文所定义。本发明的化合物可用作mGluR2抑制剂，或mGluR2负向变构调节剂（NAMs），并可用于治疗mGluR2-NAM受体参与的疾病或障碍的方法，如阿尔茨海默病、认知障碍、轻度认知障碍、精神分裂症和其他情绪障碍、疼痛障碍和睡眠障碍，通过向患者投予本发明化合物或其药学上可接受的盐的治疗有效量。本发明还涉及含有本发明化合物或其药学上可接受的盐（可选地与一个或多个额外活性成分组合）和药学上可接受的载体的药物组合物，以及在治疗这些疾病中使用本发明的化合物和药物组合物。
• Process for preparation of substituted olefins
  申请人：Rikagaku Kenkyusho

  公开号：US04263212A1

  公开（公告）日：1981-04-21

  The present invention relates to a process for the preparation of aromatic or furyl substituted olefins, which comprises reacting an olefinic compound with an aromatic compound or furan compound in the presence of carbon monoxide by using a rhodium carbonyl complex as a catalyst to form a corresponding aromatic or furyl substituted olefin.

  本发明涉及一种制备芳香或呋喃基取代烯烃的方法，包括在一种铑羰基配合物催化剂的存在下，使用一种烯烃化合物和一种芳香化合物或呋喃化合物在一氧化碳的存在下反应，形成相应的芳香或呋喃基取代烯烃。
• Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2—negative allosteric modulators, compositions, and their use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10335399B2

  公开（公告）日：2019-07-02

  The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from: and ring B, n, R1, R2, R2A, R3, and R3A are as defined herein. The compounds of the invention are useful as mGluR2 inhibitors, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a patient for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, mild cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

  本发明提供了某些取代的式 (I) 的铬烷、异铬烷和二氢异苯并呋喃化合物： 或其药学上可接受的盐，其中环 A 是选自以下的分子 和环 B、n、R1、R2、R2A、R3 和 R3A 如本文所定义。本发明的化合物可用作 mGluR2 抑制剂或 mGluR2 负性异位调节剂 (NAM)，并可用于通过向患者施用治疗有效量的本发明化合物或其药学上可接受的盐，来治疗患者涉及 mGluR2-NAM 受体的疾病或紊乱，如阿尔茨海默病、认知障碍、轻度认知障碍、精神分裂症和其他情绪紊乱、疼痛紊乱和睡眠紊乱。本发明还涉及包含本发明化合物或其药学上可接受的盐的药物组合物（可选择与一种或多种其它活性成分组合）和药学上可接受的载体，以及本发明化合物和药物组合物在治疗此类疾病中的用途。
• Chromane, isochromane and dihydroisobenzofuran derivatives as mGluR2-negative allosteric modulators, compositions, and their use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10806724B2

  公开（公告）日：2020-10-20

  The present invention provides certain substituted chromane, isochromane, and dihydroisobenzofuran compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A is a moiety selected from: and ring B, n, R1, R2, R2A, R3, and R3A are as defined herein. The compounds of the invention are useful as mGluR2 inhibitors, or mGluR2 negative allosteric modulators (NAMs), and may be useful in methods of treating a patient for diseases or disorders in which the mGluR2-NAM receptor is involved, such as Alzheimer's disease, cognitive impairment, mild cognitive impairment, schizophrenia and other mood disorders, pain disorders and sleep disorders, by administering to the patient a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof. The invention is also directed to pharmaceutical compositions comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, (optionally in combination with one or more additional active ingredients), and a pharmaceutically acceptable carrier, and the use of the compounds and pharmaceutical compositions of the invention in the treatment of such diseases.

  本发明提供了某些取代的式 (I) 的铬烷、异铬烷和二氢异苯并呋喃化合物： 或其药学上可接受的盐，其中环 A 是选自以下的分子 和环 B、n、R1、R2、R2A、R3 和 R3A 如本文所定义。本发明的化合物可用作 mGluR2 抑制剂或 mGluR2 负性异位调节剂 (NAM)，并可用于通过向患者施用治疗有效量的本发明化合物或其药学上可接受的盐，来治疗患者涉及 mGluR2-NAM 受体的疾病或紊乱，如阿尔茨海默病、认知障碍、轻度认知障碍、精神分裂症和其他情绪紊乱、疼痛紊乱和睡眠紊乱。本发明还涉及包含本发明化合物或其药学上可接受的盐的药物组合物（可选择与一种或多种其它活性成分组合）和药学上可接受的载体，以及本发明化合物和药物组合物在治疗此类疾病中的用途。
• Crisp, Geoffrey T.; O'Donoghue, Ana I., Synthetic Communications, 1989, vol. 19, # 9-10, p. 1745 - 1758
  作者：Crisp, Geoffrey T.、O'Donoghue, Ana I.

  DOI：——

  日期：——